Browse Related Topics:

Scaling Home-Based Decongestion in Heart Failure With Furoscix® (Furosemide Injection)

Despite advances in guideline-directed medical therapy, congestion from heart failure (HF) remains the principal precipitant of costly emergency department (ED) visits, readmissions and symptom burden. The upcoming Centers for Medicare & Medicaid Services (CMS) Ambulatory Specialty Model (ASM) for HF further raises the stakes, shifting accountability and financial risk to the ambulatory setting and making avoidable hospitalizations and emergency department visits a direct threat to program performance. 

Drawing on real-world experience from two U.S. health systems, this roadmap provides a scalable framework for cardiovascular leaders seeking to implement home-based decongestion with FUROSCIX® (furosemide injection) safely, efficiently and in alignment with CMS ASM and value-based care.

ACCESS ROADMAP

Ok
This site uses cookies to improve your experience.

By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.